北京若生智能科技有限公司
Drug Database
SN

snake venom antibody-2 (ViperaTAb)

✓ Approved

MicroPharm · 多克隆抗体 · 多克隆抗体

什么是 snake venom antibody-2？

snake venom antibody-2 是一种多克隆抗体，由MicroPharm研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名ViperaTAb
公司MicroPharm
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, MicroPharm

治疗适应症

snake venom antibody-2 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Injury, poisoning and procedural complicationsVenom poisoning✓ Approved

相关研究文献

PubMedAccess microbiology2026-09-10

Screening the antimicrobial properties of snake venoms: an iterative fractionation approach.

Fraser Alice J AJ, Wilkinson Mark C MC, Meehan Conor J CJ, Casewell Nicholas R NR et al.

Antimicrobial resistance increasingly poses a significant global health challenge. New antimicrobials are desperately needed, driving the need to explore novel sources of natural products. Snake venom has shown promise due to the complex mixture of proteins and peptides which demonstrate therapeutic utility in other aspects of healthcare. In this study, we took an iterative approach to screen 14 snake venoms against Escherichia coli and Klebsiella pneumoniae and identify venom-derived proteins with diverse activity against E. coli. Six venoms exhibited significant near-complete inhibitory activity, and four were retained after dialysis, confirming that the inhibitory effect was due to high-molecular-weight components above 3.5 kDa. Fractionation of two active venoms from Naja mossambica and Naja subfulva revealed protein fractions which have either subtle or significant antimicrobial activity. SDS-PAGE and mass spectrometry identified phospholipase A₂ isoforms in N. mossambica venom fractions and neurotoxic proteins (long and short neurotoxins) in N. subfulva venom fractions as potential antimicrobials.

PMID 42719680
阅读全文 →
PubMedBioinspiration & biomimetics2026-09-10

Bio-inspired Terrain Perception for Snake Robots: Spectral Analysis of Vertical Undulation and Sidewinding.

Bae Junseong J, Han DoHui D, Yun Dongwon D

While snake robots offer exceptional potential for exploration in confined and unstructured environments, their capacity for active adaptation is currently hindered by a lack of robust terrain classification. Inspired by the mechanosensory perception of biological snakes, this study proposes a proprioceptive terrain classification framework relying solely on a single uniaxial accelerometer. To capture the coupled robot-terrain interaction dynamics from the complex, non-stationary signals inherent in floating-base locomotion, we introduce the Band-Limited Spectral Magnitude (BLSM) feature, which quantifies vibratory energy within specific frequency bands. The framework was validated across four canonical terrains (concrete, gravel, grass, and sand) using two distinct locomotion modes with varying physical impact mechanisms: vertical undulation and sidewinding. However, because sidewinding generates dominant shear forces with diminished normal impacts, it introduces classification ambiguity on yielding, low-stiffness terrains. To resolve this, we implemented a hierarchical classification strategy that first categorizes bulk terrain stiffness before finely differentiating terrains within the low-stiffness group. This approach achieved classification accuracies exceeding 98.8\% for vertical undulation and up to 92.5\% for sidewinding. Notably, data-driven optimization reveals that the most effective frequency bands for terrain identification closely align with the peak sensitivity range of biological snake mechanoreceptors. By ensuring high reliability through a single scalar feature, this work establishes a practical, computationally efficient baseline for real-time, terrain-adaptive locomotion control in field applications.

PMID 42720116
阅读全文 →
PubMedAnatomical record (Hoboken, N.J. : 2007)2026-09-10

Vertebral morphology and intracolumnar variation of the iconic and bizarre viperid snake Pseudocerastes urarachnoides (Serpentes, Viperidae).

Georgalis Georgios L GL, Węgrzyn Kacper K, Ruane Sara S

We document in detail the vertebral morphology of the viperid Pseudocerastes urarachnoides, a snake from the Middle East that is famous for its extreme tail modifications with bizarre spider-like luring appendages and its caudal luring behavior that enables it to successfully prey on birds. With the aid of micro-computed tomography scanning on the holotype specimen of P. urarachnoides, we focus on the intracolumnar variation across the whole vertebral column. Interesting morphological features of the vertebrae of this species are highlighted in comparison to other viperids, particularly at the caudal vertebral portion; nevertheless, there is no evidence of any skeletal element underlying the bizarre spider-like luring appendages of the tail of P. urarachnoides. A discussion on the caudal lure and its bizarre tail scales for this peculiar species is provided.

PMID 42720717
阅读全文 →
PubMedThe Pediatric infectious disease journal2026-09-10

Immunogenicity of Single-visit, Two-site Intradermal Pre-exposure Rabies Prophylaxis in Children: A Prospective Interventional Study.

Agarwal Anurag A, Sharma Kanvi K, Mathur Surendra Bahadur SB, Manchanda Vikas V et al.

Rabies remains a major public health concern in endemic countries, particularly among children. Simplified pre-exposure prophylaxis (PrEP) schedules may improve feasibility and access in resource-limited settings and facilitate the integration of rabies vaccination into routine childhood immunization, school-based and community-based vaccination programs in rabies-endemic regions. However, pediatric data on single-visit, 2-site intradermal PrEP regimens remain limited. This study evaluated the immunogenicity and safety of a single-visit, 2-site intradermal rabies PrEP regimen in children 1-18 years of age on days 28 and 180. This prospective single-arm study enrolled healthy children 1-18 years old at a tertiary care center. Participants received a single-visit, 2-site intradermal rabies PrEP regimen with a Vero cell culture rabies vaccine (RABIVAX-S®). Anti-rabies glycoprotein immuglobulin G antibody concentrations were measured using enzyme-linked immunosorbent assay, and rabies virus neutralizing antibody concentrations were estimated by Rapid Fluorescent Focus Inhibition Test at baseline, day 28 and day 180. Participants with rabies virus neutralizing antibody concentrations <0.5 IU/mL at day 28 or day 180 received 2 intradermal booster doses on days 0 and 3 after laboratory results became available and participants returned for follow-up, followed by repeat antibody assessment 7 days after the first booster dose. The primary outcome was seroprotection (≥0.5 IU/mL). Forty-eight children were enrolled, of whom 44 were evaluated on day 28. The enrolled cohort comprised participants 2-15 years old. On day 28, 40/44 (90.9%) achieved protective antibody concentrations (≥0.5 IU/mL). Among 40 participants included in the day 180 analysis, 27 (67.5%) maintained protective concentrations. All participants with insufficient concentrations (n = 4 on day 28, n = 13 on day 180) demonstrated robust anamnestic responses following booster administration, achieving 100% seroprotection within 7 days. The regimen was well tolerated, with only mild local adverse events reported. Single-visit, 2-site intradermal rabies PrEP demonstrated high early seroprotection and preserved immunologic priming despite declining antibody concentrations at 6 months. These findings support further evaluation of simplified pediatric PrEP regimens in larger controlled studies.

PMID 42717284
阅读全文 →
PubMedNature communications2026-09-10

IL-2 mutein-engrafted antibody MHS552 selectively expands functional regulatory T cells in nonclinical models and healthy participants.

Radanović Igor I, DiDonato Michael M, Meijs Anouk C AC, Schubert David A DA et al.

Low-dose interleukin-2 (IL-2) shows potential for treating autoimmune disorders by expanding regulatory T cells (Treg), but therapeutic utility is limited by short half-life and off-target effects. Here, we describe the molecular design, nonclinical development, and first-in-human study of MHS552, an IL-2 mutein-engrafted antibody designed to selectively expand Treg via high-affinity IL-2 receptors. In vitro, MHS552 selectively induces IL-2 signaling in Treg from healthy donors and autoimmune patients. In cynomolgus monkeys, MHS552 produces dose-dependent Treg expansion, with modest increases in conventional T cells (Tconv) at higher doses. In a randomized, double-blind, placebo-controlled, single-ascending-dose trial in 60 healthy participants (EudraCT 2018-004233-33), evaluating safety and tolerability as the primary objective and pharmacokinetics as the secondary objective, intravenous and subcutaneous administration of MHS552 is well tolerated at lower doses and shows a predictable pharmacokinetic profile. However, a serious adverse event (SAE) is reported at the highest subcutaneous dose. Both administration routes result in dose-dependent Treg expansion, with up to 6-fold increase in total Treg and 60-fold increase in CD25hi subset, without significant conventional T cell activation. Exploratory analyses confirm selective Treg activation, with expanded Treg retaining their suppressive function ex vivo. These findings support IL-2-based therapeutics for autoimmune disorders, while the SAE highlights the need for careful safety evaluation.

PMID 42716926
阅读全文 →
PubMedBioinformatics advances2026-09-10

Benchmarking antibody modeling tools across structure prediction, docking, and paratope-epitope interface analysis.

Yu Zeyuan Z, Wu Jilei J, Ning Ziyao Z, Qiao Chunxia C et al.

Computational antibody engineering requires reliable prediction of antibody variable-fragment structures, antigen-antibody complexes, and binding interfaces. However, publicly available tools for these tasks have rarely been compared across the complete workflow under a controlled and statistically grounded design. We evaluated ImmuneBuilder, IgFold, AlphaFold3, GRAMM, and dyMEAN on 50 non-redundant humanized antibody-antigen complexes using multiple retained predictions and paired statistical testing. All three antibody structure predictors were accurate, with AlphaFold3 performing best overall and for the third complementarity-determining region of the heavy chain. AlphaFold3 also substantially outperformed GRAMM and dyMEAN in complex prediction, producing medium- or high-quality binding interfaces for 46% of the complexes, although overall interface accuracy remained limited. When docking was reliable, AlphaFold3 accurately recovered epitope and paratope residues, salt bridges, and non-bonded contacts, but reproduced hydrogen bonds and fine-grained contact strengths less consistently. These findings provide practical guidance for selecting tools across antibody-modeling workflows and identify persistent limitations in fine-grained interface prediction. Data, structural predictions, evaluation results, and analysis code are available from Zenodo under record 20710876.

PMID 42719814
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多snake venom antibody-2